Literature DB >> 17016854

Activation of adenosine A3 receptors reduces ischemic brain injury in rodents.

Guann-Juh Chen1, Brandon K Harvey, Hui Shen, Jenny Chou, Adrienne Victor, Yun Wang.   

Abstract

Adenosine A3 receptor (A3R) agonists have been shown to reduce cardiac and lung injury, but the protective roles of A3R agonists in the CNS are not well characterized. The protective effect of selective A3R agonist chloro-N(6)-(3-iodo-benzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA) was first examined in primary cortical cultures. In cortical culture, Cl-IB-MECA pretreatment antagonized the hypoxia-mediated decrease in cell viability. In vivo, Cl-IB-MECA or vehicle was given intracerebroventricularly or intravenously to anesthetized rats. Animals were subjected to focal cerebral ischemia induced by transient middle cerebral artery (MCA) ligation. Intracerebroventricular or repeated intravenous administration (i.e., at 165 min and 15 min before MCA ligation) of Cl-IB-MECA did not alter blood pressure during ischemia but increased locomotor activity and decreased cerebral infarction 2 days after. In these animals, Cl-IB-MECA also reduced the density of TUNEL labeling in the lesioned cortex. The possibility of endogeneous neuroprotection was further examined in A3R knockout mice. After MCA ligation, an increase in cerebral infarction was found in the A3R knockouts compared with the A3R wild-type controls, suggesting that A3Rs are tonically activated during ischemia. Additionally, intracerebroventricular pretreatment with Cl-IB-MECA decreased the size of infarction in the wild-type controls, but not in the A3R knockout animals, suggesting that Cl-IB-MECA-induced protection was mediated through the A3 receptors. Collectively, these data suggest that Cl-IB-MECA reduced cerebral infarction through the activation of A3Rs and suppression of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016854     DOI: 10.1002/jnr.21071

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  47 in total

1.  Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor.

Authors:  Athena M Keene; Ramachandran Balasubramanian; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 2.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

Review 3.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

4.  CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS.

Authors:  Maria Rosito; Cristina Deflorio; Cristina Limatola; Flavia Trettel
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

Review 5.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

6.  Controlling murine and rat chronic pain through A3 adenosine receptor activation.

Authors:  Zhoumou Chen; Kali Janes; Collin Chen; Tim Doyle; Leesa Bryant; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  FASEB J       Date:  2012-02-17       Impact factor: 5.191

7.  Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Authors:  Dale O Kiesewetter; Lixin Lang; Ying Ma; Abesh Kumar Bhattacharjee; Zhan-Guo Gao; Bhalchandra V Joshi; Artem Melman; Sonia de Castro; Kenneth A Jacobson
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

8.  Astaxanthin reduces ischemic brain injury in adult rats.

Authors:  Hui Shen; Chi-Chung Kuo; Jenny Chou; Alice Delvolve; Shelley N Jackson; Jeremy Post; Amina S Woods; Barry J Hoffer; Yun Wang; Brandon K Harvey
Journal:  FASEB J       Date:  2009-02-13       Impact factor: 5.191

9.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Sustained adenosine exposure causes lung endothelial apoptosis: a possible contributor to cigarette smoke-induced endothelial apoptosis and lung injury.

Authors:  Qing Lu; Pavlo Sakhatskyy; Julie Newton; Paul Shamirian; Vivian Hsiao; Sean Curren; Gustavo Andres Gabino Miranda; Mesias Pedroza; Michael R Blackburn; Sharon Rounds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.